Limited Submissions Opportunities

NIH Research Evaluation and Commercialization Hub (REACH) Awards
Deadline: January 23, 2019

This FOA announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof of concept work and the mentorship in product development and commercialization needed to develop high priority technologies that address the highest US disease burden within the NIH’s mission. Funded Hubs are intended to work as a consortium to enable: (1) the infrastructure for identifying the most promising technologies, (2) funding for product definition studies (e.g. feasibility studies, prototype development, proof-of-concept studies) provided to individual researchers, (3) access to expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and (4) skills development and hands-on experience in entrepreneurship.  Establishing public-private partnerships and providing additional non-federal funds will be critical for success.

Internal applications for the NIH Research Evaluation and Commercialization Hub (REACH) Awards are available on InfoReady. Investigators interested in applying must submit a 1.5 page abstract and cv.

2019 Ono Initiative LOI
Deadline: January 25, 2019

The Ono Pharma Foundation was established to support academic research in relevant scientific fields, which have the potential of making significant impact on therapeutic approaches to disease and pain management.  The Foundation’s competitive awards program, the Ono Pharma Breakthrough Science Initiative Awards Program (“Ono Initiative”), is the embodiment of the Foundation’s commitment to focus on and accelerate researcher-driven open innovation by supporting high-risk and high-reward science research projects which have potential to lead to science discoveries/solutions and, possibly, based on further research, to breakthrough treatments for patients.

 Eligibility Requirements:

Applicants must meet the following requirements. LOIs and final Proposals from applicants not meeting the requirements listed below will not be considered.

  1. Each PI applying chemical biology area must be working in one of the nominating institutions. Nominating institutions might be replaced or added to in subsequent years.
  2. Each PI applying oligonucleotide medicine research area must be working in the United States or Canada.
  3. The PI must have a MD and/or a PhD degree.
  4. The PI may not already be engaged in other sponsored research with Ono Pharmaceutical Co., Ltd. and/or grant program with Ono Pharma Foundation.
  5. The PI may not apply for funding to amplify current work. However, PIs may research a new idea based on a prior findings of the PI.

As a US private foundation, Ono Pharma Foundation grants to Canadian institutions are conditioned on an equivalency determination by the Foundation. This may require additional documentation and information from the institution outside of the application process.

Applications for the 2018 Ono Initiative are available on InfoReady. This is a limited submission that allows 2 nominations from the University of Utah.

Diabetes Research Centers (NIH P30 Clinical Trial Optional)
Deadline: February 15, 2019

This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases.  Diabetes Research Centers support two primary research-related activities:  Research Core services and a Pilot and Feasibility (P and F) program.  All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas.  The NIDDK Diabetes Research Centers program in 2018 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research.  General information about the NIDDK Diabetes Research Centers program may be found at


Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

Because a Diabetes Research Center has a large and complex administrative structure, the PD/PI must have strong leadership abilities and demonstrated proficiency in managing large, multi-component programs. The Diabetes Research Center PD(s)/PI(s) must also be willing to participate in annual meetings of the Center Directors.

Applications will be collected on InfoReady.

Subscribe to the VPR for Research News E-mail ListSubscribe to the VPR for Research News E-mail List